

Status: Currently Official on 17-Feb-2025

Official Date: Official as of 01-May-2020

Document Type: USP Monographs

DocId: GUID-4BF5E74D-FD31-4C46-9EBC-FDC85C54E9C9\_4\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M84800\\_04\\_01](https://doi.org/10.31003/USPNF_M84800_04_01)

DOI Ref: x9g5x

© 2025 USPC

Do not distribute

## Triamcinolone Diacetate

$C_{25}H_{31}FO_8$  478.51

Pregna-1,4-diene-3,20-dione, 16,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11 $\beta$ ,16 $\alpha$ )-.

9-Fluoro-11 $\beta$ ,16 $\alpha$ ,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate CAS RN<sup>®</sup>: 67-78-7; UNII: A73MM2Q32P.

» Triamcinolone Diacetate contains not less than 97.0 percent and not more than 103.0 percent of  $C_{25}H_{31}FO_8$ , calculated on the anhydrous basis.

**Packaging and storage**—Preserve in well-closed containers.

**USP REFERENCE STANDARDS (11)**—

[USP Triamcinolone Diacetate RS](#)

**Identification**—

**Change to read:**

A: ▲ [Spectroscopic Identification Tests \(197\), Infrared Spectroscopy: 197K](#)▲ (CN 1-May-2020) .

**Change to read:**

B: ▲ [Spectroscopic Identification Tests \(197\), Ultraviolet-Visible Spectroscopy: 197U](#)▲ (CN 1-May-2020) —

*Solution:* 20  $\mu$ g per mL.

*Medium:* dehydrated alcohol.

Absorptivities at 238 nm, calculated on the anhydrous basis, do not differ by more than 3.0%.

**SPECIFIC ROTATION (781S)**: between +39° and +45°.

*Test solution:* 5 mg per mL in dimethylformamide.

**WATER DETERMINATION, Method I (921)**: not more than 6.0%.

**RESIDUE ON IGNITION (281)**: not more than 0.5%.

**Assay**—

*0.005 M Monobasic sodium phosphate solution*—Dissolve monobasic sodium phosphate in water to obtain a solution containing 690  $\mu$ g per mL.

*Mobile phase*—Prepare a mixture of *0.005 M Monobasic sodium phosphate solution*, acetonitrile, and tetrahydrofuran (62:37:1), filter through a 0.45- $\mu$ m solvent-resistant filter, and degas. Make adjustments if necessary (see [System Suitability](#) under [Chromatography \(621\)](#)).

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Triamcinolone Diacetate RS](#) in *Mobile phase*, and dilute quantitatively with *Mobile phase* to obtain a solution having a known concentration of about 40  $\mu$ g per mL.

*Assay preparation*—Transfer about 50 mg of Triamcinolone Diacetate, accurately weighed, to a 50-mL volumetric flask, dissolve in *Mobile phase*, dilute with *Mobile phase* to volume, and mix. Pipet 2 mL of this solution into a second 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*System suitability preparation*—Dissolve suitable quantities of [USP Triamcinolone Diacetate RS](#) and propylparaben in *Mobile phase* to obtain a solution containing about 40  $\mu$ g per mL and 15  $\mu$ g per mL, respectively.

*Chromatographic system* (see [Chromatography \(621\)](#))—The liquid chromatograph is equipped with a 254-nm detector and a 3.9-mm  $\times$  30-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *System suitability preparation*, and record the peak responses as directed for *Procedure*: the relative retention times are 1.0 for triamcinolone diacetate and about 1.1 for propylparaben, the resolution, *R*, between the triamcinolone diacetate and propylparaben peaks is not less than 1.7, and the tailing factor, *T*, for the analyte peak is not more than 1.5. Chromatograph replicate injections of the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative standard deviation is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 10  $\mu$ L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, and measure the area responses for the major peaks. Calculate the quantity, in mg, of  $C_{25}H_{31}FO_8$  in the portion of Triamcinolone Diacetate taken

by the formula:

$$1.25C(r_u/r_s)$$

in which C is the concentration, in  $\mu\text{g}$  per mL, of [USP Triamcinolone Diacetate RS](#) in the *Standard preparation*, and  $r_u$  and  $r_s$  are the peak area responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
TRIAMCINOLONE DIACETATE	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 32(4)

**Current DocID:** [GUID-4BF5E74D-FD31-4C46-9EBC-FDC85C54E9C9\\_4\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M84800\\_04\\_01](https://doi.org/10.31003/USPNF_M84800_04_01)

**DOI ref:** [x9g5x](#)

OFFICIAL